Cardiac atrium peptide gene transfecting cell microcapsule

Abstract

An atrianatriuretic peptide gene transfected cell microcapsule is disclosed, which can be transplanted in human body to durably release human atria natriuretic peptide for treating hypertension, heat failure and renal insuficiency. It features that the human atria natriuretic peptide gene transfected immortal cells (CHO cell, COS cell, etc) is encapsulated by polycaprolactone or polyurethane microcapsule.

Description

technical field [0001] The invention relates to a gene product in medicine, especially a microcapsule product that can be implanted into a human body to continuously release human atrial peptide and treat hypertension, heart failure and renal insufficiency. Background technique [0002] Hypertension is a major disease that affects human health. The current incidence is on the rise. Hypertension has many complications: cerebrovascular disease, heart disease, kidney disease, etc. Therefore, it is imperative to find an effective treatment drug or technique. At present, hypertension is mainly treated with drugs, but there are many problems in these drugs: they must be taken regularly and for a long time, which brings a lot of inconvenience to patients; at the same time, due to strong side effects, the application time and dosage of drugs are greatly limited. [0003] Atrial peptide (ANP) is a cardiac hormone secreted primarily by the atria in response to local tension. ANP has...

AI Technical Summary

Problems solved by technology

At present, hypertension is mainly treated with drugs, but there are many problems in these drugs: they must be taken regularly and for a long time, which brings a lot of inconvenience to patients; at the same time, due to strong side effects, the application time and dosage of drugs are greatly limited

[0004] At present, ANP has been tested as a therapeutic drug (Heikki Ruskoaho, Atrialnatriuretic peptide: synthesis, release, and metabolism [J]. Pharmacological Reviews. 1992; 44: 479-602.), such as: (1) inhibition of ANP Degradation: There are no confirmed experiments to show the feasibility of using ANP analogs to inhibit the degradation of ANP in humans

(2) ANP intravenous infusion: due to the short plasma half-life of atrial peptide and its susceptibility to digestive enzymes in the gastrointestinal tract, it is difficult for atrial peptide to be administered orally

However, due to the short half-life of ANP, as a drug, it must be continuously infused, which has lost its practical value as a drug for treating hypertension.

And ANP is easily degraded by digestive enzymes, so that ANP can only be limited to intravenous administration

Diuretic and natriuretic effects have not been observed when administered by subcutaneous injection

(3) ANP receptor analogs: Although these analogs can be produced, it is still difficult to obtain specific, stable, and not easily degraded molecular forms; in addition, the synthetic analogs should be easily absorbed from the intestine It is also difficult not to be destroyed

Direct implantation of transfected cells may be an effective somatic cell therapy, but there are many disadvantages: no control over cell migration, no control over the duration of treatment